Phase I / II study of EHY2000 oncothermia therapy for advanced esophageal cancer - Phase I / II study of EHY2000 oncothermia therapy for advanced esophageal cancer

Chiba University0 个研究点目标入组 16 人开始时间: 2013年1月29日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) patients having history of hyperthermia therapy. (2) Patients with esophageal primary tumor forming a fistula. (3) Patients admitted fever with obvious infection (over 38.5 degree) (4) Seriously malnutrition (5) With pleural effusion, ascites, and pericardial which requires control (6) Heart disease (requiring hospitalization) or severe cases with a history (7) Other complications cases that require hospitalization (intestinal paralysis, intestinal obstruction, pulmonary fibrosis, diabetes control is difficult, renal failure, or cirrhosis of the liver, such as interstitial pneumonia) (8) (Patients with mental disorders are thought to require treatment or during treatment with antipsychotic drugs. (9) At the time of registration those who has cancers concurrency or has a metachronous cancers with disease-free interval less than 5 years (carcinoma in situ lesions and carcinoma in situ that are considered cured by local treatment is not included) (10) The oral or injectable steroids is under use (11) Antigen HBs, antibody HCV, HTLV-1 antibody-positive or have a history of hepatitis or HIV antibodies. (12) With a history of hypersensitivity to albumin. (13) Women with (making) the possibility of pregnancy and pregnant or lactating women. (14) Men who have intention to make pregnant. (15) Patients with autoimmune disease. (16) Cases the physician (sharing) was deemed inappropriate as the subject of the study investigator.

发起方